Cart
sales@molnova.com
Olacaftor
CAS No. 1897384-89-2
Olacaftor( VX-440 | VX440 )
Catalog No. M12980 CAS No. 1897384-89-2
Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, shows the potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 672 | In Stock |
|
| 50MG | 1962 | In Stock |
|
| 100MG | 2520 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOlacaftor
-
NoteResearch use only, not for human use.
-
Brief DescriptionOlacaftor (VX-440, VX440) is a next-generation CFTR corrector, shows the potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis.
-
DescriptionOlacaftor (VX-440, VX440) is a next-generation CFTR corrector, shows the potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis.Fibrosis Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsVX-440 | VX440
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research AreaOther Indications
-
IndicationFibrosis
Chemical Information
-
CAS Number1897384-89-2
-
Formula Weight539.666
-
Molecular FormulaC29H34FN3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (92.65 mM)
-
SMILESO=C(C1=CC=C(C2=CC(OCC(C)C)=CC(F)=C2)N=C1N3C(C)(C)C[C@H](C)C3)NS(=O)(C4=CC=CC=C4)=O
-
Chemical NameN-(benzenesulfonyl)-6-[3-fluoro-5-(2-methylpropoxy)phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
FDL169
FDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.
-
VX661
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
-
Astressin 2B
Potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist (IC50 values are 1.3 and > 500 nM for CRF2 and CRF1 respectively). Antagonizes CRF2-mediated inhibition of gastric emptying.
